Colorectal Cancer

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses combinations with targeted agents in colorectal cancer.

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.

While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses a carcinoembryonic antigen T-cell bispecific antibody.